ZPRÁVA č.4 0 PRŮBĚHU KLINICKÉHO HODNOCENÍ EWALL-INO 1.6.2022-30.5.2023 (PROGRESS REPORT No. 4 OF THE EWALL-INO CLINICAL EVALUATION 1.6.2022-30.5.2023). NA. Praha: ÚHKT PRAHA, 2023, 4 pp. NA.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name ZPRÁVA č.4 0 PRŮBĚHU KLINICKÉHO HODNOCENÍ EWALL-INO 1.6.2022-30.5.2023
Name in Czech ZPRÁVA č.4 0 PRŮBĚHU KLINICKÉHO HODNOCENÍ EWALL-INO 1.6.2022-30.5.2023
Authors
Edition NA. Praha, 4 pp. NA, 2023.
Publisher ÚHKT PRAHA
Other information
Original language English
Type of outcome Research report
Field of Study 30230 Other clinical medicine subjects
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW EWALL-INO
Organization unit Faculty of Medicine
Tags interim report, UHKT, user
Tags International impact
Changed by Changed by: Bc. Hana Vladíková, BBA, učo 244692. Changed: 15/1/2024 10:26.
Abstract
A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to EudraCT 2016-004942-27, EWALL-INO; P16/11: A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia. (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz). Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 17/5/2024 02:22